Olatoyosi Odenike to Janus Kinase 2
This is a "connection" page, showing publications Olatoyosi Odenike has written about Janus Kinase 2.
Connection Strength
0.810
-
Beyond JAK inhibitor therapy in myelofibrosis. Hematology Am Soc Hematol Educ Program. 2013; 2013:545-52.
Score: 0.437
-
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. Leukemia. 2017 02; 31(2):393-402.
Score: 0.140
-
Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol. 2011 Apr; 38(2):196-214.
Score: 0.097
-
Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat. Haematologica. 2021 09 01; 106(9):2397-2404.
Score: 0.050
-
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol. 2016 12 08; 9(1):137.
Score: 0.036
-
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. N Engl J Med. 2015 Sep 03; 373(10):920-8.
Score: 0.033
-
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006 Sep 01; 108(5):1497-503.
Score: 0.017